Openbookopenbook
Equity
GYRE
+0.0 · +0.00%
USD · NASDAQ

Gyre Therapeutics Inc.(GYRE) Stock Analysis | Healthcare

USD --+0.00%
Reward53Moderate
Risk72High
75%Data
Thin -19% profit margin
Profitless Growth
Market Cap:732.69M
ⓘ
Reward Rating
53
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
72
High
Risk Assessment
4 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GYRE to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for GYRE, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $18.67.

What is Gyre Therapeutics Inc.?

, a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.

GYRE · Verdict

Moderate reward · high risk

GYRE stands out on balance sheet and growth, but watch the volatility signal.

Based on 88% data coverage

GYRE · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet100/100

    Current ratio 5.60

  • Growth68/100

    Rev +4.5% CAGR · earnings +29.7%

Watchouts 4

  • Volatility5/100

    Weak vs peers

  • Cash flow19/100

    -0% free-cash-flow margin

  • Valuation28/100

    P/E 78.1×

  • Profitability44/100

    4% net margin · -17% ROE

Model-based scoring. For information only — not financial advice.

What is Gyre Therapeutics Inc.?

, a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 732.69M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (53)

The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

BBOTSmall Cap / 728M market cap
BridgeBio Oncology Therapeutics, Inc.
Compare
VBIZFSmall Cap / 724M market cap
Viva Biotech Holdings
Compare
NGNESmall Cap / 723M market cap
Neurogene Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap732.69M
P/E RatioN/A
Dividend YieldN/A
Beta4.815
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.